CN202699700U - Off-line hybrid bio-artificial liver support system (BALSS) - Google Patents
Off-line hybrid bio-artificial liver support system (BALSS) Download PDFInfo
- Publication number
- CN202699700U CN202699700U CN 201220303275 CN201220303275U CN202699700U CN 202699700 U CN202699700 U CN 202699700U CN 201220303275 CN201220303275 CN 201220303275 CN 201220303275 U CN201220303275 U CN 201220303275U CN 202699700 U CN202699700 U CN 202699700U
- Authority
- CN
- China
- Prior art keywords
- blood
- detection sensor
- press detection
- plasma
- blood bag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000004185 liver Anatomy 0.000 title claims description 26
- 210000004369 blood Anatomy 0.000 claims abstract description 145
- 239000008280 blood Substances 0.000 claims abstract description 145
- 239000012530 fluid Substances 0.000 claims abstract description 48
- 210000002381 plasma Anatomy 0.000 claims description 63
- 238000001514 detection method Methods 0.000 claims description 56
- 238000002560 therapeutic procedure Methods 0.000 claims description 32
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 24
- 238000001179 sorption measurement Methods 0.000 claims description 23
- 238000004891 communication Methods 0.000 claims description 15
- 238000002616 plasmapheresis Methods 0.000 claims description 15
- 230000001413 cellular effect Effects 0.000 claims description 9
- 238000004159 blood analysis Methods 0.000 claims description 7
- 210000003850 cellular structure Anatomy 0.000 claims description 5
- 238000012546 transfer Methods 0.000 claims description 3
- 238000011282 treatment Methods 0.000 abstract description 30
- 239000002699 waste material Substances 0.000 abstract description 4
- 238000000034 method Methods 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 238000012545 processing Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 3
- 230000001951 hemoperfusion Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 229940126587 biotherapeutics Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Images
Landscapes
- External Artificial Organs (AREA)
Abstract
The utility model discloses an off-line hybrid BALSS the BALSS which comprises a plasma exchange device, a treatment device and a second blood bag which is provided with a waste plasma inlet and a feedback plasma outlet, wherein a waste plasma outlet of the plasma exchange device is communicated with the waste plasma inlet through fluid, the feedback plasma outlet is communicated with a first blood bag which is used for supplying plasma for a human body, and a fluid inlet and a fluid outlet of the treatment device are communicated with the second flood bag through the fluid. The BALSS has the advantages that the treatment effect is good, the safety factor is high, and blood consumption for patients is saved.
Description
Technical field
This utility model relates to a kind of artificial liver support system, particularly the hybrid biological artificial liver support system of a kind of offline model.
Background technology
At present, the application at home and abroad of abiotic type artificial liver supporting technology is very extensive and ripe, becomes gradually one of most important and the most frequently used Therapeutic Method of hepatitis gravis, liver failure and other some diseases.In recent years, the progress that learns a skill along with appearance and the tissue biological of novel biomaterial, occurred take the Biotype artificial liver of culture hepatocyte as the basis, in conjunction with the improvement of cell culture technology, the abiotic mixed biology artificial liver back-up system that combines with biotype has been subject to people's extensive concern.
Various treatment flow processs in the existing equipment and this flow scheme design overlap, but flow scheme design is all different.Artificial liver in treatment is divided into abiotic type and biotype two large classes, and existing treatment flow process focuses mostly in abiotic type therapeutic process, perhaps single biotype therapeutic process.Abiotic type mainly is plasmapheresis, plasma perfusion and albumen filtration etc.The mixed biologic treatment is used seldom in the liver failure treatment flow process of existing clinical practice, usually be sectional therapy, or two machines is treated alternately.
Chinese patent literature CN101455864A discloses a kind of mixed biology artificial liver vitro supporting device, blood samples of patients is through successively through the part plasmapheresis, plasma perfusion, bioartificial liver and get back to after hemodialysis in the patient body, this is a kind of online artificial liver vitro supporting device, to the processing of blood samples of patients and be to carry out continuously in the blood recovery patient body after processing, this just needs this device very strong to the disposal ability of blood samples of patients, careless slightlyly will cause undesirable blood recovery in patient body, bring life danger to the patient, safety stability coefficient is lower.In addition, if the blood after processing does not meet the requirement that feeds back in the patient body, also can pollute the fresh plasma that flows into blood pool from plasma bags, also can pollute the erythrocyte that the self-separation pipe flow enters blood pool simultaneously; Thereby cause the waste of fresh blood, affect therapeutic effect, the extended treatment time.
The utility model content
For the deficiencies in the prior art, the purpose of this utility model is to provide that a kind of therapeutic effect is good, safety coefficient is high and save the hybrid biological artificial liver support system of offline model of patient's blood using amount.
The technical solution of the utility model is achieved in that the hybrid biological artificial liver support system of offline model, comprise plasmapheresis device and therapy equipment, also comprise the second blood bag with useless plasma inlet and autoplamotherapy outlet, useless blood plasma outlet and the described useless plasma inlet fluid communication of described plasmapheresis device, described autoplamotherapy outlet and the first blood bag fluid communication, described the first blood bag is used for supplying with blood plasma in human body, the fluid intake of described therapy equipment and fluid issuing respectively with described the second blood bag fluid communication.
The hybrid biological artificial liver support system of above-mentioned offline model, described plasmapheresis device comprises the first press detection sensor, the first blood pump, the second press detection sensor, plasma separator, the 3rd press detection sensor, leak blood examination and survey device and the second blood pump, the fluid intake of described plasma separator and blood of human body delivery outlet fluid communication, described the first press detection sensor, described the first blood pump and described the second press detection sensor are successively set on from the blood of human body delivery outlet to the blood transportation tube between the fluid intake of described plasma separator, plasma fraction outlet and the described useless plasma inlet fluid communication of described plasma separator, described the 3rd press detection sensor, described leakage blood examination is surveyed device and described the second blood pump and is successively set on plasma fraction from described plasma separator and is exported on the blood plasma transfer pipeline between the described useless plasma inlet, is exported to from the cell component of described plasma separator on the pipeline of human body and is disposed with the 4th press detection sensor, the first pinch valve and ultrasonic bubble detector.
The hybrid biological artificial liver support system of above-mentioned offline model, described the first blood bag is by the pipeline fluid conducting between human body Blood transfusion tubeline and described plasma separator and described the 4th press detection sensor; From described the first blood bag, be disposed with the 3rd blood pump and pipeline heater at described human body Blood transfusion tubeline.
The hybrid biological artificial liver support system of above-mentioned offline model, described therapy equipment comprise Molecular Adsorption therapy equipment and biological respinse therapy equipment.
The hybrid biological artificial liver support system of above-mentioned offline model, described Molecular Adsorption therapy equipment comprises the second pinch valve, the 5th press detection sensor, bilirubin adsorption device, the 6th press detection sensor and the 4th blood pump, described the 5th press detection sensor and described the second pinch valve are successively set on from the fluid issuing of described bilirubin adsorption device to the pipeline between described the second blood bag, and described the 4th blood pump and described the 6th press detection sensor are successively set on from described the second blood bag to the pipeline between the fluid intake of described bilirubin adsorption device.
The hybrid biological artificial liver support system of above-mentioned offline model, the biological respinse therapy equipment comprises the 5th blood pump, the 7th press detection sensor, bioreactor, cellular filter, the 8th press detection sensor and the 3rd pinch valve, described the 5th blood pump and described the 7th press detection sensor are successively set on from described the second blood bag to the pipeline between the fluid intake of described bioreactor, described cellular filter, described the 8th press detection sensor and described the 3rd pinch valve are successively set on from the fluid issuing of described bioreactor to the pipeline between described the second blood bag.
The hybrid biological artificial liver support system of above-mentioned offline model, described the first blood bag and described the second blood bag lay respectively on the match bascule.
The beneficial effects of the utility model are: blood circuit and patient keep off-line in molecular adsorbent recycling system and biological respinse treatment cyclic process, the physical parameters such as its flow, pressure should be subjected to condition without any affecting on patient's physiology, safety stability coefficient is high, treatment time shortens greatly, has reduced simultaneously the use amount of blood plasma; Guaranteed greatly patient's treatment safety in the therapeutic process.
Solved the problems such as safety that the uninterrupted continuously treatment of integrated mixed biologic artificial liver brings is low, solved the long problem for the treatment of time span, shortened in a large number the patient time, and saved patient's blood using amount; Also solve abiotic treatment and biological respinse and treated inharmonic contradiction.
Description of drawings
Fig. 1 is the structural representation of the hybrid biological artificial liver support system of this utility model offline model.
Among the figure: 1-the first blood bag, 2-the second blood bag, 3-the first press detection sensor, 4-the first blood pump, 5-the second press detection sensor, 6-plasma separator, 7-the 3rd press detection sensor, 8-the second blood pump, 9-the 4th press detection sensor, 10-ultrasonic bubble detector, 11-the 3rd blood pump, the 12-pipeline heater, 13-the second pinch valve, 14-the 5th press detection sensor, 15-bilirubin adsorption device, 16-the 6th press detection sensor, 17-the 4th blood pump, 18-the 5th blood pump, 19-the 7th press detection sensor, the 20-bioreactor, the 21-cellular filter, 22-the 8th press detection sensor, 23-the first pinch valve, 24-leaks blood examination and surveys device, 25-the 3rd pinch valve.
The specific embodiment
By reference to the accompanying drawings this utility model is described further:
As shown in Figure 1, the hybrid biological artificial liver support system of present embodiment offline model, comprise plasmapheresis device and therapy equipment, also comprise the second blood bag 2 with useless plasma inlet and autoplamotherapy outlet, useless blood plasma outlet and the described useless plasma inlet fluid communication of described plasmapheresis device, described autoplamotherapy outlet and the first blood bag 1 fluid communication, described the first blood bag 1 is used for supplying with blood plasma in human body, the fluid intake of described therapy equipment and fluid issuing respectively with described the second blood bag 2 fluid communication.
Described plasmapheresis device comprises the first press detection sensor 3, the first blood pump 4, the second press detection sensor 5, plasma separator 6, the 3rd press detection sensor 7, leak blood examination and survey device 24 and the second blood pump 8, the fluid intake of described plasma separator 6 and blood of human body delivery outlet fluid communication, described the first press detection sensor 3, described the first blood pump 4 and described the second press detection sensor 5 are successively set on from the blood of human body delivery outlet to the blood transportation tube between the fluid intake of described plasma separator 6, plasma fraction outlet and the described useless plasma inlet fluid communication of described plasma separator 6, described the 3rd press detection sensor 7, described leakage blood examination is surveyed device 24 and described the second blood pump 8 and is successively set on plasma fraction from described plasma separator 6 and is exported on the blood plasma transfer pipeline between the described useless plasma inlet, is exported to from the cell component of described plasma separator 6 on the pipeline of human body and is disposed with the 4th press detection sensor 9, the first pinch valve 23 and ultrasonic bubble detector 10.Described the first blood bag 1 is by the pipeline fluid conducting between human body Blood transfusion tubeline and described plasma separator 6 and described the 4th press detection sensor 9; From described the first blood bag 1, be disposed with the 3rd blood pump 11 and pipeline heater 12 at described human body Blood transfusion tubeline.
In the present embodiment, described therapy equipment comprises Molecular Adsorption therapy equipment and biological respinse therapy equipment.Described Molecular Adsorption therapy equipment comprises the second pinch valve 13, the 5th press detection sensor 14, bilirubin adsorption device 15, the 6th press detection sensor 16 and the 4th blood pump 17, described the 5th press detection sensor 14 and described the second pinch valve 13 are successively set on from the fluid issuing of described bilirubin adsorption device 15 to the pipeline between described the second blood bag 2, and described the 4th blood pump 17 and described the 6th press detection sensor 16 are successively set on from described the second blood bag 2 to the pipeline between the fluid intake of described bilirubin adsorption device 15.Described biological respinse therapy equipment comprises the 5th blood pump 18, the 7th press detection sensor 19, bioreactor 20, cellular filter 21, the 8th press detection sensor 22 and the 3rd pinch valve 25, described the 5th blood pump 18 and described the 7th press detection sensor 19 are successively set on from described the second blood bag 2 to the pipeline between the fluid intake of described bioreactor 20, described cellular filter 21, described the 8th press detection sensor 22 and described the 3rd pinch valve 25 are successively set on from the fluid issuing of described bioreactor 20 to the pipeline between described the second blood bag 2.Described the first blood bag 1 and described the second blood bag 2 lay respectively on the match bascule, with amount from fresh blood to human body that realize replenishing with equate from the isolated plasma volume of human body.
Blood in the patient body enters into described plasma separator 6 through described the first blood pump 4,6 pairs of blood samples of patients of described plasma separator are carried out cell component and are separated with plasma fraction, the cell component direct feedback of separating is in patient body, and the plasma fraction of separating is transported to described the second blood bag 2 through described the second blood pump 8.Described the 4th blood pump 17 is transported to again described the second blood bag 2 with the blood transport in described the second blood bag 2 after described bilirubin adsorption device 15 carries out adsorption treatment.Described the 5th blood pump 18 is transported to described the second blood bag 2 with processing by described cellular filter 21 in the described bioreactor 20 of blood transport in described the second blood bag 2.Do not meet when feeding back in the patient body at the blood of described the second blood bag 2, described bilirubin adsorption device 15 and described bioreactor 20 can be processed the blood circulation of described the second blood bag 2, until the blood in described the second blood bag 2 reaches the standard that feeds back in the patient body.When the blood in described the second blood bag 2 reaches when feeding back to the patient body internal standard, the blood transport of described the second blood bag 2 is stored in described the first blood bag 1, in order in patient body, feed back.
The plasmapheresis flow process is finished in power support by described the first blood pump 4, the second blood pump 8 and the 3rd blood pump 3, and described the first blood bag 1 interior prior storage fresh plasma is as patient's in advance displacement blood plasma.
Finish the hemoperfusion flow process by the 17 power supports of described the 4th blood pump, coordinate to carry out with the plasmapheresis flow process, described the second blood bag 2 satisfies a certain amount of blood collecting amount for collecting the useless blood bag of displacement in early stage by the electronic scale measurement, can start this flow process.
Finish the Biotherapeutics flow process by pump 5 power supports, carry out 1.5 hours such as adsorbing therapy after, begin to carry out biological respinse treatment early-stage preparations and flushing, after everything is ready, the beginning Biotherapeutics.Described bioreactor 20 is positioned on the interior bioreactor reel cage platform of incubator, and according to treatment and biological culture requirement, described bioreactor 20 is in the spatial environments of constant temperature cleaning all the time, gives oxygen supply simultaneously in described cellular filter 21.In this stage, three flow process treatments are carried out at the same time.
Described plasma separator 6, described bilirubin adsorption device 15 represents respectively three kinds of different therapeutic processes with described bioreactor 20, described the first blood bag 1 is fluid infusion bag, described the second blood bag 2 is useless blood reclaiming bag, described the first blood pump 4 is the blood sampling pump, described the second blood pump 8 is separate pump, described the 3rd blood pump 7 is the fluid infusion pump, described the 4th blood pump 17 and described the 5th blood pump 18 are respectively the Molecular Adsorption treatment and the biological respinse treatment provides the hemodynamic support, the whole blood circulation flow path is provided with 8 pressure monitoring points altogether, provides respectively blood sampling to press, venous pressure, transmembrane pressure, Molecular Adsorption and biological respinse treatment, calculating and the monitoring of pressure behind the device such as the cellular filter film cephacoria.Described pipeline heating device 12 is guaranteed the constant temperature of loop blood to adopt simultaneously ultrasonic bubble detector 10 and described the first pinch valve 23 linkages, guarantees to enter without bubble in the blood of loop.Blood circuit and patient keep off-line in molecular adsorbent recycling system and biological respinse treatment cyclic process, have guaranteed greatly patient's treatment safety in the therapeutic process.
When the hybrid biological artificial liver support system of the offline model of present embodiment solves the treatment of mixed biologic artificial liver off-line, carry out plasmapheresis and hemoperfusion treatment.Adopt plasmapheresis and hemoperfusion to carry out blood purification, so that the maximization of therapeutic effect.Described Molecular Adsorption therapy equipment and described biological respinse therapy equipment all are to be in the off-line treatment stage, are in minimum for patient's security implication.
This utility model is integrated biological and abiotic artificial liver in treatment scientific order.Because the flow scheme design of described therapy equipment is the purification treatment that only is directed to the useless blood plasma in described the second blood bag 2, be in the indirect joint relation with online patient, so be referred to as off-line, the physical parameters such as its flow, pressure should be subjected to condition without any affecting on patient's physiology, safety stability coefficient is high, treatment time shortens greatly, has reduced simultaneously the use amount of blood plasma.
Above-described embodiment only is for the invention example clearly is described, and is not the restriction to the invention specific embodiment.For those of ordinary skill in the field, can also make other changes in different forms on the basis of the above description.Here need not also can't give all embodiments exhaustive.And the apparent variation of being extended out thus or change still are among the protection domain of the invention claim.
Claims (1)
1. the hybrid biological artificial liver support system of offline model, comprise plasmapheresis device and therapy equipment, it is characterized in that, also comprise the second blood bag (2) with useless plasma inlet and autoplamotherapy outlet, useless blood plasma outlet and the described useless plasma inlet fluid communication of described plasmapheresis device, described autoplamotherapy outlet and the first blood bag (1) fluid communication, described the first blood bag (1) is used for supplying with blood plasma in human body, the fluid intake of described therapy equipment and fluid issuing respectively with described the second blood bag (2) fluid communication; Described plasmapheresis device comprises the first press detection sensor (3), the first blood pump (4), the second press detection sensor (5), plasma separator (6), the 3rd press detection sensor (7), leak blood examination and survey device (24) and the second blood pump (8), the fluid intake of described plasma separator (6) and blood of human body delivery outlet fluid communication, described the first press detection sensor (3), described the first blood pump (4) and described the second press detection sensor (5) are successively set on from the blood of human body delivery outlet to the blood transportation tube between the fluid intake of described plasma separator (6), plasma fraction outlet and the described useless plasma inlet fluid communication of described plasma separator (6), described the 3rd press detection sensor (7), described leakage blood examination is surveyed device (24) and described the second blood pump (8) and is successively set on plasma fraction from described plasma separator (6) and is exported on the blood plasma transfer pipeline between the described useless plasma inlet, is exported to from the cell component of described plasma separator (6) on the pipeline of human body and is disposed with the 4th press detection sensor (9), the first pinch valve (23) and ultrasonic bubble detector (10); Described the first blood bag (1) is by the pipeline fluid conducting between human body Blood transfusion tubeline and described plasma separator (6) and described the 4th press detection sensor (9); From described the first blood bag (1), be disposed with the 3rd blood pump (11) and pipeline heater (12) at described human body Blood transfusion tubeline; Described therapy equipment comprises Molecular Adsorption therapy equipment and biological respinse therapy equipment; Described Molecular Adsorption therapy equipment comprises the second pinch valve (13), the 5th press detection sensor (14), bilirubin adsorption device (15), the 6th press detection sensor (16) and the 4th blood pump (17), described the 5th press detection sensor (14) and described the second pinch valve (13) are successively set on from the fluid issuing of described bilirubin adsorption device (15) to the pipeline between described the second blood bag (2), and described the 4th blood pump (17) and described the 6th press detection sensor (16) are successively set on from described the second blood bag (2) extremely on the pipeline between the fluid intake of described bilirubin adsorption device (15); The biological respinse therapy equipment comprises the 5th blood pump (18), the 7th press detection sensor (19), bioreactor (20), cellular filter (21), the 8th press detection sensor (22) and the 3rd pinch valve (25), described the 5th blood pump (18) and described the 7th press detection sensor (19) are successively set on from described the second blood bag (2) to the pipeline between the fluid intake of described bioreactor (20), described cellular filter (21), described the 8th press detection sensor (22) and described the 3rd pinch valve (25) are successively set on from the fluid issuing of described bioreactor (20) to the pipeline between described the second blood bag (2); Described the first blood bag (1) and described the second blood bag (2) lay respectively on the match bascule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201220303275 CN202699700U (en) | 2012-06-27 | 2012-06-27 | Off-line hybrid bio-artificial liver support system (BALSS) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201220303275 CN202699700U (en) | 2012-06-27 | 2012-06-27 | Off-line hybrid bio-artificial liver support system (BALSS) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN202699700U true CN202699700U (en) | 2013-01-30 |
Family
ID=47580048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201220303275 Expired - Fee Related CN202699700U (en) | 2012-06-27 | 2012-06-27 | Off-line hybrid bio-artificial liver support system (BALSS) |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN202699700U (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103263705A (en) * | 2013-05-09 | 2013-08-28 | 浙江大学 | Plasma exchange absorption filter purifying system with square plasma storage tank |
| CN103263706A (en) * | 2013-05-09 | 2013-08-28 | 浙江大学 | Plasma storage bag special for plasma exchange, absorption, and filtration treatment |
| CN104225698A (en) * | 2014-09-03 | 2014-12-24 | 西安交通大学 | Hepatocyte microsphere bioartificial liver supporting system |
| CN108211032A (en) * | 2018-02-01 | 2018-06-29 | 南方医科大学珠江医院 | Combination type biological Artificial Liver Support System |
| CN110141706A (en) * | 2019-06-14 | 2019-08-20 | 科先医疗科技(苏州)有限公司 | A kind of Biotype artificial liver circulatory support system |
-
2012
- 2012-06-27 CN CN 201220303275 patent/CN202699700U/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103263705A (en) * | 2013-05-09 | 2013-08-28 | 浙江大学 | Plasma exchange absorption filter purifying system with square plasma storage tank |
| CN103263706A (en) * | 2013-05-09 | 2013-08-28 | 浙江大学 | Plasma storage bag special for plasma exchange, absorption, and filtration treatment |
| CN104225698A (en) * | 2014-09-03 | 2014-12-24 | 西安交通大学 | Hepatocyte microsphere bioartificial liver supporting system |
| CN104225698B (en) * | 2014-09-03 | 2016-04-13 | 西安交通大学 | A kind of hepatocyte microsphere circulating biological artificial liver support system |
| CN108211032A (en) * | 2018-02-01 | 2018-06-29 | 南方医科大学珠江医院 | Combination type biological Artificial Liver Support System |
| CN108211032B (en) * | 2018-02-01 | 2023-11-17 | 南方医科大学珠江医院 | Combined bioartificial liver support system |
| US11911552B2 (en) | 2018-02-01 | 2024-02-27 | Southern Medical University Zhujiang Hospital | Combined bio-artificial liver support system |
| CN110141706A (en) * | 2019-06-14 | 2019-08-20 | 科先医疗科技(苏州)有限公司 | A kind of Biotype artificial liver circulatory support system |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN202699700U (en) | Off-line hybrid bio-artificial liver support system (BALSS) | |
| JP5106102B2 (en) | Metabolic detoxification system and method | |
| CN102389594B (en) | Portable blood purifying system | |
| CN109069719A (en) | System or equipment and method for dialysing | |
| WO2018201862A1 (en) | Circulating tumor cell capture device | |
| CN108430529A (en) | system and method for extracorporeal blood treatment | |
| CN104800902A (en) | Extracorporeal circulation life supporting device for treating and curing multiple organ failure | |
| CN104225698B (en) | A kind of hepatocyte microsphere circulating biological artificial liver support system | |
| CN202497518U (en) | Continuous blood purifying treatment apparatus | |
| CN206228667U (en) | A kind of Biotype artificial liver | |
| CN202207346U (en) | Portable blood purifying system | |
| CN205515729U (en) | Blood purifying device and system | |
| CN202122732U (en) | Water-saving type artificial kidney | |
| CN202069913U (en) | Disposable virus inactivation blood transfusion set | |
| CN203379412U (en) | Portable device used for peritoneal dialysis treatment and pipeline thereof | |
| CN203598288U (en) | Hybrid bioartificial liver pipeline | |
| CN106039446B (en) | A kind of wearable peritoneal dialysis portable unit | |
| WO2016015371A1 (en) | Bio-artificial liver system | |
| CN203244631U (en) | Plasma storage bag for plasma exchange, absorbing and filtering treatment | |
| CN206334152U (en) | A kind of regulating system for blood purification | |
| CN205386253U (en) | Bioartificial liver on -line monitoring and integrative system of constant temperature heating | |
| CN203329103U (en) | Double-pump hemodialysis machine used for conducting plasma adsorption treatment | |
| CN206334150U (en) | A kind of haemodialysis equipment | |
| CN201862019U (en) | Connecting bag special for matched plasma exchange, filtration and adsorption treatment | |
| CN110975040A (en) | Blood purification system special for children and application of blood purification system in blood purification of children |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: 3RD MILITARY HOSPITAL OF CHINA 02 HOSPITAL Free format text: FORMER OWNER: YOU SHAOLI Effective date: 20130227 Free format text: FORMER OWNER: RONG YIHUI Effective date: 20130227 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20130227 Address after: 100039 third. Two hospital of PLA, 100 middle Fourth Ring Road, Fengtai District, Beijing Patentee after: 302 Military Hospital of China Address before: 100039 No.302 Hospital of PLA, 100 middle Fourth Ring Road, Fengtai District, Beijing Patentee before: You Shaoli Patentee before: Rong Yihui |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130130 Termination date: 20150627 |
|
| EXPY | Termination of patent right or utility model |